BVS · NASDAQ
Bioventus (BVS) Stock Price & Fundamentals
Bioventus (BVS) closed at $477.89 on Oct 9, 2026, down 1.27% from the previous close of $484.03.
Share price, past year
1Y +22.55%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $477.89 |
| Sep 30, 2026 | $489.69 |
| Aug 31, 2026 | $487.96 |
| Jul 31, 2026 | $497.97 |
| Jun 30, 2026 | $481.26 |
| May 29, 2026 | $458.00 |
| Apr 30, 2026 | $474.26 |
| Mar 31, 2026 | $476.62 |
| Feb 27, 2026 | $472.98 |
| Jan 30, 2026 | $474.91 |
| Dec 31, 2025 | $467.53 |
| Nov 28, 2025 | $465.90 |
| Oct 31, 2025 | $424.99 |
Key statistics
- Market cap
- —
- P/E (TTM)
- 620.6
- EPS (TTM)
- $0.77
- Revenue (TTM)
- $581.85M
- Net income (TTM)
- $54.46M
- Shares outstanding
- —
- Dividend yield
- —
- 52-week range
- $388.63 – $511.62
Financials
Bioventus reported revenue of $568.09M for fiscal 2025, down 0.91% from fiscal 2024.
Bioventus earned net income of $22.73M in fiscal 2025, a net margin of 4.0%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $568.09M | −0.9% | $22.73M | 4.0% | $0.33 | $72.11M |
| FY2024ended Dec 31, 2024 | $573.28M | +11.9% | −$36.13M | −6.3% | −$0.56 | $37.79M |
| FY2023ended Dec 31, 2023 | $512.35M | 0.0% | −$156.23M | −30.5% | −$2.49 | $7.98M |
| FY2022ended Dec 31, 2022 | $512.12M | +18.9% | −$158.70M | −31.0% | −$2.59 | −$15.02M |
| FY2021ended Dec 31, 2021 | $430.90M | +34.2% | $19.38M | 4.5% | −$0.15 | $9.47M |
| FY2020ended Dec 31, 2020 | $321.16M | −5.6% | $16.41M | 5.1% | — | $55.22M |
| FY2019ended Dec 31, 2019 | $340.14M | — | $6.85M | 2.0% | — | $38.37M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 27, 2026 | $153.21M | $33.44M | $0.47 |
| Q1 FY2026ended Mar 28, 2026 | $132.09M | $3.11M | $0.04 |
| Q4 FY2025ended Dec 31, 2025 | $157.90M | $14.76M | $0.21 |
| Q3 FY2025ended Sep 27, 2025 | $138.65M | $3.16M | $0.05 |
| Q2 FY2025ended Jun 28, 2025 | $147.66M | $7.46M | $0.11 |
| Q1 FY2025ended Mar 29, 2025 | $123.88M | −$2.64M | −$0.04 |
| Q4 FY2024ended Dec 31, 2024 | $153.64M | −$388.00K | $0.00 |
| Q3 FY2024ended Sep 28, 2024 | $138.96M | −$5.17M | −$0.08 |
Company profile
- Name
- Bioventus Inc.
- Ticker
- BVS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Surgical & Medical Instruments & Apparatus
- Headquarters
- 4721 Emperor Boulevard, Suite 100, Durham, NC 27703
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001665988
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 4, 2026
- May 21, 2026
- May 6, 2026
- May 6, 2026
- Mar 5, 2026
- Mar 5, 2026
Frequently asked questions
What is Bioventus's stock price?
Bioventus (BVS) closed at $477.89 on Oct 9, 2026, down 1.27% from the previous close of $484.03.
How much revenue does Bioventus make?
Bioventus reported revenue of $568.09M for fiscal 2025, down 0.91% from fiscal 2024.
What is BVS's P/E ratio?
Bioventus's price-to-earnings ratio is 620.6, based on trailing twelve-month diluted EPS of $0.77.
Does Bioventus pay a dividend?
Bioventus's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Bioventus Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures